Clinical trial
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine…
NCT00435409 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00435409 |
|---|---|
| Title | A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer |
| Official title | A Randomized, Phase 3 Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Previously Treated Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Sunitinib + Capecitabine, Capecitabine |
| Enrollment | 442 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Jun 1, 2011 |
| First posted | Feb 15, 2007 |
| Last update posted | Jun 26, 2012 |
| Countries | Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Norway and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: